Chief, Section of Critical Care Cardiology University of California San Francisco

Printed as of 4/21/2025

Disclosures

Personal Commercial (6)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---------------------|---------------------------|--------------------|---|
| Self | | | |
| Abbott Laboratories | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Abiomed | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Acceleron | Research/Research Grants | Modest (< \$5,000) | Pulmonary Hypertension and Venous Thromboembolic |
| Bayer | Consultant Fees/Honoraria | Modest (< \$5,000) | Pulmonary Hypertension and Venous Thromboembolic |
| Merck & Co., Inc. | Research/Research Grants | Modest (< \$5,000) | Pulmonary Hypertension and Venous Thromboembolic |
| Zoll | Consultant Fees/Honoraria | Modest (< \$5,000) | Arrhythmias and Clinical EP |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (1)

| Non-Commercial Enity Name | Relationship Category | Compensation Level | Topic Area(s) |
|--|---------------------------|--------------------|---------------|
| Self | | | |
| American Board of Internal Medicine † none | Consultant Fees/Honoraria | Modest (< \$5,000) | Other |

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

| Year | Case Title | Represented | Description | Compensation |
|------|-------------------|-------------|---|--------------------|
| Self | | | | |
| 2023 | Cardiogenic shock | Plaintiff | Patient had unrecognized cardiogenic shock. Shared expertise on recognition of cardiogenic shock. | Modest (< \$5,000) |

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 11/8/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 11/8/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/Confidentiality Disclosure and Assignment Agreement Agreement and Assignment Agreement and Assignment Agreement Agre

Embargo | Signed on 11/8/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 11/8/2024

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.